Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Protein Effect||no effect|
|Gene Variant Descriptions||FGFR3 amp indicates an increased number of copies of the FGFR3 gene. However, the mechanism causing the increase is unspecified.|
|Associated Drug Resistance|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR3 amp||Advanced Solid Tumor||predicted - sensitive||Ponatinib||Preclinical||Actionable||In a preclinical study, Iclusig (ponatinib) inhibited growth of several tumor cell lines with FGFR alterations in culture (Cancer Res April 15, 2011 71:3560).||detail...|
|FGFR3 amp||lung non-small cell carcinoma||sensitive||PRN1371||Preclinical - Pdx||Actionable||In a preclinical study, PRN1371 treatment resulted in 28.2% tumor growth inhibition in patient-derived xenograft models of FGFR3-amplified non-small cell lung cancer (PMID: 28978721).||28978721|
|FGFR3 amp||urinary system cancer||sensitive||AZD4547||Preclinical - Cell culture||Actionable||In a preclinical study, AZD4547 decreased Myc expression, induced cell cycle arrest, and inhibited growth of a urinary tract cancer cell line harboring FGFR3 amplification in culture (PMID: 27401245).||27401245|
|FGFR3 amp||urinary system cancer||sensitive||Infigratinib||Preclinical - Cell culture||Actionable||In a preclinical study, Infigratinib (BGJ398) decreased Myc expression, induced cell cycle arrest, and inhibited growth of a urinary tract cancer cell line harboring FGFR3 amplification in culture (PMID: 27401245).||27401245|
|FGFR3 amp||Advanced Solid Tumor||predicted - sensitive||Debio 1347||Phase I||Actionable||In a Phase I trial, Debio 1347 treatment resulted in partial response in 10.5% (6/57) and stable disease in 28.1% (16/57) of patients with advanced solid tumors harboring genomic alterations of FGFR1/2/3, including amplifications, fusions, and mutations (PMID: 30745300; NCT01948297).||30745300|
|ROS1 fusion ERBB2 amp FGFR3 amp RET amp||lung non-small cell carcinoma||predicted - resistant||Crizotinib||Case Reports/Case Series||Actionable||In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor presumed resistance alterations, including amplification of ERBB2 (HER2), FGFR3, and RET (PMID: 29636358).||29636358|